Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 4, 141-7
eCollection

Oncolytic Sendai Virus-Based Virotherapy for Cancer: Recent Advances

Affiliations
Review

Oncolytic Sendai Virus-Based Virotherapy for Cancer: Recent Advances

Kotaro Saga et al. Oncolytic Virother.

Abstract

Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development of new therapeutic technologies, in addition to new anticancer drugs, is necessary for more effective oncotherapy. Oncolytic viruses are one potential new anticancer strategy. Various oncolytic viruses have been developed for safe and effective oncotherapy. Recently, Sendai virus-based oncotherapy has been reported by several groups, and attention has been drawn to its unique anticancer mechanisms, which are different from those of the conventional oncolytic viruses that kill cancer cells by cancer cell-selective replication. Here, we introduce Sendai virus-based virotherapy and its anticancer mechanisms.

Keywords: HVJ-E; anticancer immunity; apoptosis; cancer therapy; necroptosis.

Figures

Figure 1
Figure 1
Structure of Sendai virus. Abbreviation: HVJ, hemagglutinating virus of Japan.
Figure 2
Figure 2
Schematic representation of HVJ-E-mediated cancer cell death. Notes: (A) HVJ-E-mediated apoptosis signaling in cancer cells with CASP8. RNA fragments, which are introduced by HVJ-E membrane fusion, are recognized by RIG-I, and the signaling induces the transcription of TRAIL and Noxa by the activation of IRF7 and IRF3 via the RIG-I/MAVS pathway. TRAIL activates CASP8 via TRAIL receptor binding, and Noxa activates CASP9 via Cyt-C release from mitochondria. Activation of CASP8 and CASP9 results in cancer cell apoptosis via the subsequent activation of CASP3. (B) HVJ-E-mediated necroptosis signaling in cancer cells without CASP8. HVJ-E membrane fusion elevates the cytoplasmic Ca2+ level, and Ca2+ induces the phosphorylation of CaMK II. CaMK-II-P phosphorylates RIP1, and RIP1-P induces cancer cell necroptosis by elevating the levels of intracellular ROS. Abbreviations: CaMK-II-P, phosphorylated CaMK II; CASP, caspase; Cyt-C, cytochrome-C; HVJ-E, ultraviolet-irradiated hemagglutinating virus of Japan; RIP1-P, phosphorylated RIP1; ROS, reactive oxygen species; TRIAL, TNF-related apoptosis-inducing ligand.

Similar articles

See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles

References

    1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–670. - PMC - PubMed
    1. Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett. 2007;254(2):178–216. - PubMed
    1. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274(5286):373–376. - PubMed
    1. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559–567. - PubMed
    1. Bell J, McFadden G. Viruses for tumor therapy. Cell Host Microbe. 2014;15(3):260–265. - PMC - PubMed

LinkOut - more resources

Feedback